Catalyst Pharmaceuticals, Inc.
Index- P/E29.68 EPS (ttm)0.50 Insider Own7.30% Shs Outstand102.80M Perf Week7.21%
Market Cap1.55B Forward P/E17.54 EPS next Y0.85 Insider Trans-9.90% Shs Float94.95M Perf Month36.80%
Income54.50M PEG- EPS next Q0.19 Inst Own76.30% Short Float7.15% Perf Quarter107.39%
Sales170.50M P/S9.12 EPS this Y-48.10% Inst Trans7.05% Short Ratio3.18 Perf Half Y98.80%
Book/sh2.35 P/B6.33 EPS next Y20.80% ROA22.40% Target Price16.90 Perf Year186.51%
Cash/sh2.11 P/C7.04 EPS next 5Y- ROE25.10% 52W Range4.81 - 15.07 Perf YTD119.65%
Dividend- P/FCF- EPS past 5Y29.80% ROI19.00% 52W High-0.86% Beta1.32
Dividend %- Quick Ratio10.40 Sales past 5Y- Gross Margin84.60% 52W Low210.60% ATR0.80
Employees76 Current Ratio10.80 Sales Q/Q45.90% Oper. Margin42.70% RSI (14)68.88 Volatility5.42% 6.26%
OptionableYes Debt/Eq0.00 EPS Q/Q75.00% Profit Margin32.00% Rel Volume3.05 Prev Close14.87
ShortableYes LT Debt/Eq0.00 EarningsAug 09 AMC Payout0.00% Avg Volume2.13M Price14.94
Recom2.00 SMA206.82% SMA5035.52% SMA20083.85% Volume1,292,867 Change0.47%
Aug-24-22Downgrade ROTH Capital Buy → Neutral $10 → $15.50
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-07-18Resumed Piper Jaffray Overweight
Oct-05-16Upgrade Piper Jaffray Neutral → Overweight
Apr-26-16Downgrade Piper Jaffray Overweight → Neutral $6 → $1
Sep-30-14Reiterated ROTH Capital Buy $5 → $6
Sep-16-14Reiterated ROTH Capital Buy $3.50 → $5
Sep-15-14Reiterated H.C. Wainwright Buy $5 → $13
Oct-21-13Reiterated Aegis Capital Buy $4 → $5.50
Sep-24-13Initiated Maxim Group Buy $4
Sep-06-13Reiterated Aegis Capital Buy $3.50 → $4
Apr-18-13Initiated Aegis Capital Buy $2.50
Aug-27-12Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $3.70
Oct-01-09Upgrade Merriman Sell → Neutral
May-29-09Downgrade Merriman Curhan Ford Buy → Sell
May-29-09Downgrade Hapoalim Neutral → Underperform
Dec-15-08Initiated Merriman Curhan Ford Buy
Nov-28-07Initiated Rodman & Renshaw Mkt Outperform $9
Jan-31-07Initiated Stifel Nicolaus Buy $9
Jan-05-07Initiated First Albany Buy $10
Sep-05-22 01:46PM  
Aug-26-22 12:45PM  
Aug-24-22 08:03AM  
Aug-23-22 10:53AM  
Aug-09-22 06:35PM  
Jul-26-22 08:03AM  
Jul-14-22 06:01AM  
Jul-12-22 06:00AM  
Jun-25-22 08:15AM  
Jun-09-22 11:30AM  
Jun-04-22 11:07AM  
May-17-22 08:03AM  
May-11-22 06:05AM  
May-10-22 05:25PM  
May-09-22 05:45PM  
Apr-25-22 08:03AM  
Apr-05-22 06:41PM  
Mar-29-22 05:15PM  
Mar-16-22 05:45PM  
Mar-11-22 08:03AM  
Mar-09-22 03:00PM  
Mar-08-22 08:03AM  
Mar-03-22 09:20AM  
Mar-02-22 08:03AM  
Feb-28-22 10:00AM  
Feb-24-22 08:03AM  
Feb-17-22 08:03AM  
Feb-15-22 10:41AM  
Feb-11-22 08:50AM  
Feb-10-22 10:00AM  
Feb-08-22 09:49AM  
Feb-07-22 08:03AM  
Feb-03-22 08:03AM  
Jan-28-22 01:46PM  
Jan-16-22 07:05AM  
Jan-10-22 08:03AM  
Jan-05-22 07:25AM  
Jan-04-22 07:30AM  
Dec-20-21 06:23AM  
Dec-06-21 07:00AM  
Dec-02-21 05:13AM  
Nov-15-21 04:15PM  
Nov-09-21 06:35PM  
Nov-04-21 08:50AM  
Nov-02-21 03:02PM  
Oct-25-21 08:03AM  
Oct-18-21 08:24AM  
Oct-12-21 08:50AM  
Oct-08-21 07:21AM  
Sep-30-21 12:08PM  
Sep-17-21 08:03AM  
Sep-10-21 08:03AM  
Sep-08-21 11:30AM  
Aug-16-21 08:03AM  
Aug-09-21 06:55PM  
Aug-02-21 03:01PM  
Jul-26-21 08:03AM  
Jul-23-21 04:03AM  
Jul-19-21 08:03AM  
Jul-06-21 08:03AM  
Jun-29-21 08:03AM  
Jun-28-21 04:30PM  
Jun-16-21 02:38AM  
Jun-09-21 11:30AM  
Jun-03-21 03:09PM  
May-19-21 08:03AM  
May-11-21 06:30AM  
May-10-21 07:05PM  
May-08-21 06:12AM  
May-03-21 03:01PM  
Apr-14-21 11:30AM  
Apr-05-21 01:03AM  
Mar-22-21 08:03AM  
Mar-21-21 04:42AM  
Mar-18-21 06:02PM  
Mar-16-21 10:38AM  
Mar-15-21 06:45PM  
Mar-08-21 12:30PM  
Mar-04-21 11:00AM  
Feb-22-21 08:03AM  
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GRANDE ALICIAVP, Treasurer and CFOAug 29Sale14.2057,000809,560407,442Aug 30 05:00 PM
GRANDE ALICIAVP, Treasurer and CFOAug 26Sale14.4011,095159,768464,442Aug 30 05:00 PM
Daly Richard JDirectorAug 24Option Exercise2.5340,000101,20092,666Aug 26 05:01 PM
Tierney David SDirectorAug 22Option Exercise2.5320,00050,600328,207Aug 23 05:01 PM
Tierney David SDirectorAug 22Sale14.1620,000283,180308,207Aug 23 05:01 PM
MCENANY PATRICK JPresident and CEOAug 19Option Exercise2.53125,000316,2505,055,217Aug 19 05:02 PM
MCENANY PATRICK JPresident and CEOAug 19Sale14.10125,0001,762,4254,930,217Aug 19 05:02 PM
GRANDE ALICIAVP, Treasurer and CFOAug 18Option Exercise2.5319,25948,725494,796Aug 19 05:02 PM
Miller SteveChief Operating OfficerAug 18Option Exercise2.53150,000379,500880,299Aug 19 05:03 PM
O'Keeffe Charles BDirectorAug 18Option Exercise2.5340,000101,200653,042Aug 19 05:03 PM
MCENANY PATRICK JPresident and CEOAug 18Option Exercise2.53175,000442,7504,980,217Aug 19 05:02 PM
MCENANY PATRICK JPresident and CEOAug 18Sale13.94175,0002,440,3504,930,217Aug 19 05:02 PM
Miller SteveChief Operating OfficerAug 18Sale13.53150,0002,029,922761,724Aug 19 05:03 PM
GRANDE ALICIAVP, Treasurer and CFOAug 18Sale13.7019,259263,848475,537Aug 19 05:02 PM
GRANDE ALICIAVP, Treasurer and CFOAug 17Option Exercise2.53130,741330,775574,853Aug 19 05:02 PM
COELHO PHILIP HDirectorAug 17Option Exercise2.5340,000101,200279,553Aug 19 05:02 PM
GRANDE ALICIAVP, Treasurer and CFOAug 17Sale13.86130,7411,811,635475,537Aug 19 05:02 PM
INGENITO GARYChief Medical & Reg. OfficerJun 22Option Exercise4.136,15225,40828,205Jun 23 05:02 PM
INGENITO GARYChief Medical & Reg. OfficerJun 22Sale6.616,15240,64622,053Jun 23 05:02 PM
INGENITO GARYChief Medical & Reg. OfficerJun 21Option Exercise4.13143,848594,092165,901Jun 23 05:02 PM
INGENITO GARYChief Medical & Reg. OfficerJun 21Sale6.59143,848948,67822,053Jun 23 05:02 PM
Tierney David SDirectorMay 20Option Exercise2.5320,00050,600328,207May 24 04:30 PM
Daly Richard JDirectorJan 25Option Exercise3.3550,000167,50052,666Jan 26 05:29 PM
DENKHAUS DONALD ADirectorJan 10Option Exercise2.5340,000101,200317,666Jan 11 06:22 PM
DENKHAUS DONALD ADirectorJan 05Option Exercise3.3550,000167,500277,666Jan 06 04:50 PM
INGENITO GARYChief Medical OfficerDec 07Sale6.993,61225,23722,053Dec 08 05:01 PM